Iveric bio announced the design of a second pivotal trial for Zimura, a complement C5 inhibitor in development for the treatment of geographic atrophy.
Following the positive results of a phase 2b trial, the company plans to randomly assign 400 patients to receive monthly doses of either Zimura (avacincaptad pegol) 2 mg or a controlled sham, according to a press release.
“In the first trial, both the Zimura 2 mg and Zimura 4 mg doses met the primary efficacy endpoint at month 12 with statistical significance and similar efficacy as (Read more...)
Uncategorized